M&A analysis: Genmab bucks the bargain basement trend
The group’s $8bn acquisition of Merus was the standout in the third quarter.
FDA red and green lights: September 2025
A single-arm trial was enough for J&J’s Inlexzo nod.
ESMO 2025 preview – Merck hopes for Daiichi redemption
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
The month ahead: October’s upcoming events
ESMO and the Triple Meeting approach.
ESMO 2025 preview – Enhertu's early breast hat-trick
The ESMO presidential session will feature data from Destiny-Breast05 and 11.
Zelgen’s DLL3 trispecific goes pivotal
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
ESMO 2025 preview – IO Biotech's hollow victory
Keynote-D18 features among the ESMO late-breakers, but IO Biotech can't file.
Merck shoots for KRAS all comers
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
